Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561284 | 0.88 | HTT (0.64) | ALOX5HTTSMN1; SMN2GAAMEN1 | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.88 | SMN1; SMN2 (0.60) | ALOX5HTTSMN1; SMN2GAAMEN1 | |
| SCHEMBL15171158 | 0.87 | ALOX5 (0.49) | ALOX5HTTSMN1; SMN2GAAMEN1 | |
| SCHEMBL16177702 | 0.86 | HTT (0.50) | ALOX5HTTSMN1; SMN2GAAMEN1 | |
| SCHEMBL1099548 | 0.85 | MEN1 (0.55) | ALOX5HTTSMN1; SMN2GAAMEN1 | |
| SCHEMBL31191372 | 0.85 | ALDH1A1 (0.53) | ALOX5HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2367158 | 0.84 | NPC1 (0.68) | ALOX5HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL16245017 | 0.84 | KMT2A (0.54) | ALOX5HTTSMN1; SMN2GAAMEN1 | |
| SCHEMBL27893481 | 0.84 | HTT (0.52) | ALOX5HTTSMN1; SMN2GAAMEN1 | |
| SCHEMBL2664523 | 0.84 | GAA (0.55) | ALOX5HTTSMN1; SMN2GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720034-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | Zydus Lifesciences Limited (IN) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024252254-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-12-12 | — | — | WO | disclosed |
| CN-118510770-A | Fused heteroaryl hydroxamic acids as STING agonists | 比西切姆有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-112789087-B | Benzimidazole inhibitors of PAD enzymes | 百时美施贵宝公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-111108105-B | Heterocyclic compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115298175-A | Macrocyclic PAD4 inhibitors useful as immunosuppressants | 百时美施贵宝公司 | 2022-11-04 | — | — | CN | disclosed |
| US-10322998-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-6187804-B1 | Antibiotic compounds | ZENECA LIMITED (GB) | 2001-02-13 | — | — | US | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5856321-A | PREPARATION OF CARBAPENEMS | ZENECA LIMITED (GB) | 1999-01-05 | — | — | US | disclosed |
| EP-0579826-B1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| US-5652233-A | CARBAPENICILLINS | ZENECA LIMITED (GB) | 1997-07-29 | — | — | US | disclosed |
| US-5478820-A | Carbapenem deivatives; bactericides | ZENECA LTD. (GB) | 1995-12-26 | — | — | US | disclosed |
| EP-0579826-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993015078-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322998-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | DNPEP, PRKCSH, BCAT1 | ALOX5 4743/4885HTT 733/4885SMN1; SMN2 4002/4885 |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | ALOX5 1653/4885HTT 3793/4885SMN1; SMN2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.